Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-820-0 | CAS number: 74-89-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable, well-documented publication which meets basic scientific principles, tested substance was methylamine hydrochloride.
Data source
Reference
- Reference Type:
- publication
- Title:
- Further studies on the metabolism of methylamine by semicarbazide-sensitive amine oxidase activities in human plasma, umbilical artery and rat aorta
- Author:
- Lyles, G.A., Holt, A. and Marshall, C.M.S.
- Year:
- 1 990
- Bibliographic source:
- J.Phar. Pharmacol. 1990, 42: 322-338
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Deviations:
- no
- GLP compliance:
- no
Test material
- Reference substance name:
- Methylammonium chloride
- EC Number:
- 209-795-0
- EC Name:
- Methylammonium chloride
- Cas Number:
- 593-51-1
- Molecular formula:
- CH5N.ClH
- IUPAC Name:
- methanaminium chloride
- Reference substance name:
- monomethylamine hydrochloride
- IUPAC Name:
- monomethylamine hydrochloride
- Details on test material:
- [14C]methylamine hydrochloride (55 µCi/µmol) and [7-14C]benzylamine hydrochloride (51 µCi/µmol). Unlabelled amine was added to give 100 mM stock solutions at final specific activities of [ (MA) and 0-5 µCi /µmol (BZ) which were stored frozen between experiments.
BZ served as a competitive inhibitor of an enzym, which metabolizes both BZ and MA.
Constituent 1
Constituent 2
- Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- The animals were obtained from the Departmental breeding colony, Animal Services Unit, University of Dundee.
The animals served only as a source of aorta. The metabolism of MA was studies in the homogenates of the aorta.
Human plasma and umbilical artery were also used for studying of the MA metabolism. Human umbilical cords were supplied by the Maternity Unit, Ninewells Hospital, usually from deliveries involving Caesarean sections.
For studies on human plasma, blood (approx. 20 mL) was cotlected by antecubital venepuncture from four healthy male volunteers (age range 22-38 years) into glass tubes without anticoagulant, allowed to clot and then centrifuged (1700 g for 10 min). The serum was removed, divided into several smaller portions and stored as above for subsequent use in experiments.
Administration / exposure
- Route of administration:
- other: added to blood vessels homogenates
- Vehicle:
- not specified
- Duration and frequency of treatment / exposure:
- Colorimetric amine oxidase assay: incubations for 30 min of [14C]MA hydrochloride with the homogenates prepared above.
Radiochemical amine oxidase assay: In some inhibitor studies, samples were preincubated with inhibitors for 20 min at 37°C before further ice-cooling and addition of substrate. Samples were then incubated at 37°C for either 30 min (umbilical artery), 60 min (aorta) or 120 min (plasma).
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Radiochemical amine oxidase assay: Assays, in triplicates, (25 µL enzyme source, 25 µL distilled water (or aqueous inhibitor solution, in inhibitor studies) and 50 µL appropriate [l4C]MA concentration (prepared in 0-2 M potassium phosphate buffer pH 7-8)).
Dialysis studies: 50 µL 2mM of [14C]MA
- No. of animals per sex per dose / concentration:
- not applicable
- Positive control reference chemical:
- Assays performed without competitive inhibitors of MA metabolism.
Competitive inhibitors used: clorgyline and semicarbazide - Details on study design:
- The following tests were performed:
1. Comparison of MA metabolism determined by colorimetric and radiochemical assay.
2. Effects of clorgyline and semicarbazide upon MA metabolism in rat aorta, human umbilical artery and plasma.
3. The determination of kinetic constants for MA metabolism in rat aorta, human umbilical artery and plasma.
4. Inhibition of [14C]MA metabolism in human umbilical artery and plasma by unlabelled BZ.
5. Kinetic constants for (14C]BZ metabolism in human umbilical artery and product formation from mixtures of[14C]BZ and [14C]MA.
6. Effects of β-aminopropionitrile (BAPN) upon MA metabolism in human umbilical artery - Details on dosing and sampling:
- 1. Comparison of MA metabolism determined by colorimetric and radiochemical assay: Three homogenates from different umbilical arteries were assayed concurrently by the two methods at a final MA concentration of 1 mM.
2. Effects of clorgyline and semicarbazide upon MA metabolism in rat aorta, human umbilical artery and plasma: Tissue homogenates or plasma samples were preincubated with inhibitor concentrations from 0.1 µM to 1 mM, and remaining enzyme activity was determined with 1 mM [14C]MA as substrate in the ion exchange assay, and compared with activity in control samples preincubated without inhibitor.
3. Kinetic constants for MA metabolism in rat aorta, human umbilical artery and plasma: The metabolism of [14C]MA was measured at final assay concentrations of 0.05-1 mM in rat aorta, and 0.1-2 mM in human umbilical artery homogenates.
4. Inhibition of [14C]MA metabolism in human umbilical artery and plasma by unlabelled BZ: Assays of [14C]MA metabolism (0.2-2 mM in umbilical artery, 0.1-1 mM in plasma) were carried out in the presence of unlabelled BZ at final assay concentrations of 100, 200 or 400 µM.
5. Kinetic constants for (14C]BZ metabolism in human umbilical artery and product formation from mixtures of [14C]BZ and [14C]MA: the [14C] metabolite formation from 200 µM [14C]BZ and 800 µM [14C]MA, these substrates being used both individually and also as a mixture with each homogenate tested.
6. Effects of β-aminopropionitrile (BAPN) upon MA metabolism in human umbilical artery: the effects of 100, 200 and 500 µM BAPN upon the deamination of 0-2-2 mM MA. - Statistics:
- not reported
Results and discussion
- Preliminary studies:
- listed in the original paper
Main ADME results
- Type:
- metabolism
- Results:
- MA is a substrate for the semicarbazide-sensitive amine oxidase (SSAO)
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Vt was determined. Vt=product formation from a mixture of the two substrates (A and B). Specific inhibition of MMA-metabolism by semicarbazide. These results suggest that MA is predominantly, if not exclusively, a substrate for the soluble amine oxidase in human plasma.
Any other information on results incl. tables
1.Comparison of MA metabolism determined by colorimetric and radiochemical assay:
Mean (± S.E.) specific enzyme activities for the group were 281 ± 32 nmol H2O2 (mg protein)/1 h for the colorimetric assay and 366 ± 31 nmol MA metabolized (mg protein)/1 h for the radiochemical assay.
2.Effects of clorgyline and semicarbazide upon MA metabolism in rat aorta, human umbilical artery and plasma:
The deamination of both MA and BZ was largely resistant to inhibition by clorgyline concentrations up to 1 mM, whereas similar concentrations of semicarbazide produced a progressive degree of inhibition which resulted in virtually complete inhibition of MA metabolism, and around 80% inhibition of BZ metabolism at 1 mM semicarbazide. These results suggest that MA is predominantly, if not exclusively, a substrate for the soluble amine oxidase in human plasma.
3. Kinetic constants for MA metabolism in rat aorta, human umbilical artery and plasma
Mean values (± S.E.) from four different samples were: Km(µM) of 516 ± 74 (MA) and 225 ± 36 (BZ): Vmax (nmol (mL serum)/1 h) of 48 ± 5 (MA) and 28 ± 3(BZ).
4. Inhibition of [14C]MA metabolism in human umbilical artery and plasma by unlabelled BZ
BZ was found to be a competitive inhibitor of MA metabolism. Mean values (± S.E.) for Ki (µM) from experiments with different samples of each enzyme source were 220 ±10 (umbilical artery, n=3) and 172 ± 27 (plasma, n=4).
5. Kinetic constants for (14C]BZ metabolism in human umbilical artery and product formation from mixtures of[14C]BZ and [14C]MA
200 µM [14C]BZ and 800 µM [14C]MA were cocultivated with homogenates of human umbilical artery. The substrate concentrations were chosen to approximate closely to their Km values-found in the earlier work reported in the original paper. If a single enzyme metabolizes two different substrates at the same catalytic site, the product formation calculated (for detailed calculations see original paper) should be comparable with that experimentally determined. Table 1 shows the results obtained in this experiment:
Table 1. Comparison of predicted and actual metabolite formation in mixtures of [14C]BZ and [14C]MA. |
|||||
Expt. no. |
vA |
vB |
Predicted vT |
Actual vT |
Ratio (Actual vT/ Predicted vT) |
d min-1 |
d min-1 |
d min-1 |
d min-1 |
|
|
1 |
623 |
3526 |
2832 |
2743 |
0.97 |
2 |
577 |
3460 |
2757 |
2822 |
1.02 |
3 |
858 |
5401 |
4274 |
4759 |
1.11 |
4 |
721 |
4481 |
3552 |
3681 |
1.04 |
|
|
|
|
Mean ratio= 1.04 ± 0.03 |
|
vAand vBrepresent [14C]metabolite formation (in d min-1) from 200 µMBZ and 800 µMMA, respectively, in assays containing the appropriate amine individually. The predicted metabolite formation (vT) from a mixture of the two amines if metabolized by the same enzyme was determined as described in the text, and compared with actual experimentally determined values. Experiments were carried out on 4 different arteries, assays on each artery involving concurrent determinations (in triplicate) of BZ and MA metabolism alone, and in a mixture. |
6. Effects of β-aminopropionitrile (BAPN) upon MA metabolism in human umbilical artery
BAPN was found to be a competitive inhibitor of MA metabolism
Applicant's summary and conclusion
- Conclusions:
- SSAO metabolizes MA.
The vasculature and plasma contain semicarbazide-sensitive amine oxidase (SSAO) which metabolizes MA - Executive summary:
Lyles et al. investigated in 1990 the metabolism of methylamine hydrochloride in vitro. An ion exchange radiochemical assay has been developed to study the deamination of [14C]methylamine (MA) in homogenates of rat aorta and human umbilical artery, as well as in samples of human plasma. MA metabolism was found to be inhibited almost completely by 1 mM semicarbazide, but virtually unaffected by 0-1 mM clorgyline, suggesting that MA is a substrate for the semicarbazide-sensitive amine oxidase (SSAO) activities which also metabolize benzylamine (BZ) in these sources. Mean Km values for MA metabolism by aorta, umbilical artery and plasma were 182, 832 and 516 µM, respectively, with corresponding Vmax values in aorta and umbilical artery of 100 and 590 nmol /(mg prot.) h, and in plasma of 48 nmol /(mL serum) h. Kinetic constants determined for [14C]BZ metabolism in plasma (by an organic solvent extraction assay) and in umbilical artery (by the ion exchange assay) yielded mean Km values of 225 µM (plasma), 222 µM (umbilical artery), and Vmax values of 28 nmol (mL serum)/ 1 h (plasma) and 377 nmol /(mg prot.) h (umbilical artery). The deamination of [14C]MA was inhibited competitively by unlabelled BZ, with Ki values in umbilical artery and plasma of 220 and 172 µM, respectively. Also, metabolite formation from mixtures of [14C]BZ (200 µM) and [14C]MA (800 µM) was extremely close to that predicted for a single enzyme capable of metabolizing two alternative substrates in a competitive fashion. β-Aminopropionitrile was found to be a reversible, competitive inhibitor (Ki of 165 µM) of [14C]MA metabolism in umbilical artery, inhibitory properties characteristic of those found previously for the effects of β-aminopropionitrile upon BZ-metaboIizing SSAO activities in other tissues.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.